Important note: Information in this article was accurate in October 2006. The state of the art may have changed since the publication date.
FDA decision delayed on Biojector for administering T-20 pending additional safety information
HIV Treat Bull - 2006 October;7(10):
On 12 October, Roche issued a press release relating to the timeline for the FDA decision on the Biojector 2000 system that is currently being studied in an open label expanded access trial in the US.
Several small studied reported that many patients found this needle-free device, which fires T-20 through the skin under pressure, reduced the severity of injection site reactions, and improved quality of life.
In the larger safety study, a small proportion of patients have experienced haemotoma and nerve damage, largely relating to when the device has been used in site with earlier scar tissue or near bone - both of which are not recommended as injection sites in the prescribing information for T-20.
Collecting additional data on these events will probably delay the FDA decision until early 2007.
It is expected that this will have a similar effect on regulatory decisions in Europe. Currently, unless they have been able to purchase this privately in the US, UK patients do not have access to the Biojector.
Source: Roche press release (12 October, 2006)
2006-10-10
IB060710-11
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.